baltimore conference logo
  • MJHLS Brand Logo

© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Expert Perspective Tumor Board

Virtual Tumor Board

Targeted Oncology presents Expert Perspective Virtual Tumor Board. a video editorial series featuring multi-disciplinary collaboration between professionals reviewing patient cases and discussing diagnoses, biomarker testing, and treatment strategies.

Graft-Versus-Host Disease

Case 1: GvHD Background
Case 1: GvHD Background
Case 1: A Patient With Acute Graft-Vs-Host Disease
Case 1: A Patient With Acute Graft-Vs-Host Disease
Case 1: Staging of Acute Graft-vs-Host Disease
Case 1: Staging of Acute Graft-vs-Host Disease
Case 1: Personal Approach to Treatment for Acute GVHD
Case 1: Personal Approach to Treatment for Acute GVHD
Case 2: Steroid-Refractory Acute Graft-Versus-Host Disease
Case 2: Steroid-Refractory Acute Graft-Versus-Host Disease
Case 2: Ruxolitinib for Steroid-Refractory Acute GVHD
Case 2: Ruxolitinib for Steroid-Refractory Acute GVHD
Case 2: Treating Steroid-Refractory Acute GVHD
Case 2: Treating Steroid-Refractory Acute GVHD

Ovarian Cancer

Adjuvant Chemotherapy + Bevacizumab for Ovarian Cancer
Adjuvant Chemotherapy + Bevacizumab for Ovarian Cancer
An Overview of PARP Inhibitors in Ovarian Cancer
An Overview of PARP Inhibitors in Ovarian Cancer
Pivotal Trials in the Realm of Ovarian Cancer
Pivotal Trials in the Realm of Ovarian Cancer
Case 1: Diagnostic Tissue Testing in Ovarian Cancer
Case 1: Diagnostic Tissue Testing in Ovarian Cancer
Case 1: Use of Maintenance Therapy in Ovarian Cancer
Case 1: Use of Maintenance Therapy in Ovarian Cancer
Case 1: Observation Versus Maintenance Therapy in Ovarian Cancer
Case 1: Observation Versus Maintenance Therapy in Ovarian Cancer
Case 1: Impact of Biomarkers on Maintenance Therapy
Case 1: Impact of Biomarkers on Maintenance Therapy
Case 1: Use of Niraparib in Ovarian Cancer
Case 1: Use of Niraparib in Ovarian Cancer
Case 2: Adding Bevacizumab to Chemotherapy in Ovarian Cancer
Case 2: Adding Bevacizumab to Chemotherapy in Ovarian Cancer
Case 2: Maintenance in BRCA1/2wt, HR-Proficient Ovarian Cancer
Case 2: Maintenance in BRCA1/2wt, HR-Proficient Ovarian Cancer
Case 3: Second-Line Therapy for Recurrent Ovarian Cancer
Case 3: Second-Line Therapy for Recurrent Ovarian Cancer
Case 3: Maintenance Therapy for Recurrent Ovarian Cancer
Case 3: Maintenance Therapy for Recurrent Ovarian Cancer
Case 3: The OCEANS and GOG-0213 Trials for Ovarian Cancer
Case 3: The OCEANS and GOG-0213 Trials for Ovarian Cancer
Case 3: Benefit of PARP Inhibitor Maintenance in Ovarian Cancer
Case 3: Benefit of PARP Inhibitor Maintenance in Ovarian Cancer
Treating Ovarian Cancer With a PFI Less Than 6 Months
Treating Ovarian Cancer With a PFI Less Than 6 Months
Trials of Interest in Ovarian Cancer
Trials of Interest in Ovarian Cancer

Myeloproliferative Neoplasms

Case 1: A 68-Year-Old Woman With Primary Myelofibrosis
Case 1: A 68-Year-Old Woman With Primary Myelofibrosis
Case 1: Risk Stratification Models for Myelofibrosis
Case 1: Risk Stratification Models for Myelofibrosis
Case 1: NCCN Guidelines for Treating Myelofibrosis
Case 1: NCCN Guidelines for Treating Myelofibrosis
Case 1: Ruxolitinib Treatment for Myelofibrosis
Case 1: Ruxolitinib Treatment for Myelofibrosis
Case 1: Fedratinib Treatment for Myelofibrosis
Case 1: Fedratinib Treatment for Myelofibrosis
Case 1: The Diagnosis of Myelofibrosis
Case 1: The Diagnosis of Myelofibrosis
Case 1: Transformation of Myelofibrosis to AML
Case 1: Transformation of Myelofibrosis to AML
Case 1: Initiating Therapy for Myelofibrosis
Case 1: Initiating Therapy for Myelofibrosis
Case 2: A 67-Year-Old Male With Polycythemia Vera
Case 2: A 67-Year-Old Male With Polycythemia Vera
Case 2: NCCN Guidelines for Treating Polycythemia Vera
Case 2: NCCN Guidelines for Treating Polycythemia Vera
Case 2: The RESPONSE Trial of Ruxolitinib for PV
Case 2: The RESPONSE Trial of Ruxolitinib for PV
Case 2: The Diagnosis of Polycythemia Vera
Case 2: The Diagnosis of Polycythemia Vera
Case 2: Ruxolitinib Treatment for Polycythemia Vera
Case 2: Ruxolitinib Treatment for Polycythemia Vera
Case 3: A 39-Year-Old Female With Essential Thrombocythemia
Case 3: A 39-Year-Old Female With Essential Thrombocythemia
Case 3: Prediction of Thrombosis in Essential Thrombocythemia
Case 3: Prediction of Thrombosis in Essential Thrombocythemia
Case 3: Low- to Intermediate- Risk Essential Thrombocythemia
Case 3: Low- to Intermediate- Risk Essential Thrombocythemia
Case 3: Management of Essential Thrombocythemia
Case 3: Management of Essential Thrombocythemia
Case 3: Risk Assessment of Essential Thrombocythemia
Case 3: Risk Assessment of Essential Thrombocythemia
Transformation of Essential Thrombocythemia
Transformation of Essential Thrombocythemia
Case 4: A 68-Year-Old Man With Primary Myelofibrosis
Case 4: A 68-Year-Old Man With Primary Myelofibrosis
Case 4: Risk Factors and Genetic Abnormalities of MPN
Case 4: Risk Factors and Genetic Abnormalities of MPN
Case 4: MPN Transition From Chronic- to Blast-Phase MPN
Case 4: MPN Transition From Chronic- to Blast-Phase MPN
Case 4: Assessing Risk for Transformation to AML
Case 4: Assessing Risk for Transformation to AML
Case 4: The Importance of Early Intervention in MPN
Case 4: The Importance of Early Intervention in MPN

Breast Cancer

Case 1: Early-Stage HER2+ Breast Cancer
Case 1: Early-Stage HER2+ Breast Cancer
Case 1: Decision Making in Early Stage HER2+ Breast Cancer
Case 1: Decision Making in Early Stage HER2+ Breast Cancer
Case 1: Guidelines for HER2 Testing in Breast Cancer
Case 1: Guidelines for HER2 Testing in Breast Cancer
Case 1: When to Use FISH Testing in Breast Cancer
Case 1: When to Use FISH Testing in Breast Cancer
Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
Case 1: Treatment for Early-Stage HER2+ Breast Cancer
Case 1: Treatment for Early-Stage HER2+ Breast Cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Case 2: ER+ Breast Cancer
Case 2: ER+ Breast Cancer
Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer
Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer
Case 2: Treatment Recommendations for ER+ Breast Cancer
Case 2: Treatment Recommendations for ER+ Breast Cancer
Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
Case 3: Metastatic Triple-Negative Breast Cancer
Case 3: Metastatic Triple-Negative Breast Cancer
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
Case 3: PD-L1 Testing Used in Triple-Negative Breast Cancer
Case 3: PD-L1 Testing Used in Triple-Negative Breast Cancer
Case 3: Managing Immune-Related Adverse Effects in TNBC
Case 3: Managing Immune-Related Adverse Effects in TNBC
Case 3: Treatment After Progression in Triple-Negative Breast Cancer
Case 3: Treatment After Progression in Triple-Negative Breast Cancer
Case 4: BRCA+ Metastatic Breast Cancer
Case 4: BRCA+ Metastatic Breast Cancer
Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC
Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC
Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC
Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer
Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer
Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
Case 4: Looking Forward in BRCA+ Metastatic TNBC
Case 4: Looking Forward in BRCA+ Metastatic TNBC

Clinical Cases in Chronic Lymphocytic Leukemia

Case 1: Newly Diagnosed CLL, IGHV-Unmutated
Case 1: Newly Diagnosed CLL, IGHV-Unmutated
Case 1: Initiating Treatment for CLL
Case 1: Initiating Treatment for CLL
Case 1: Assessing Risk in CLL
Case 1: Assessing Risk in CLL
Case 1: The Use of Ibrutinib in CLL
Case 1: The Use of Ibrutinib in CLL
Case 1: Ibrutinib +/- CD20 Antibodies in CLL
Case 1: Ibrutinib +/- CD20 Antibodies in CLL
Case 1: Ibrutinib in CLL
Case 1: Ibrutinib in CLL
Case 2: Newly Diagnosed CLL; Del(17p)
Case 2: Newly Diagnosed CLL; Del(17p)
Case 2: Frontline Treatments for CLL With Del(17p)
Case 2: Frontline Treatments for CLL With Del(17p)
Case 2: MRD Testing in CLL
Case 2: MRD Testing in CLL
Case 2: Choosing Treatment for CLL With Del(17p)
Case 2: Choosing Treatment for CLL With Del(17p)
Case 2: Sequencing Therapies in CLL
Case 2: Sequencing Therapies in CLL
Case 3: Elderly Patient With Treatment-Naive CLL
Case 3: Elderly Patient With Treatment-Naive CLL
Case 3: Managing Ibrutinib-Associated Toxicities in CLL
Case 3: Managing Ibrutinib-Associated Toxicities in CLL
Case 3: Risk Assessment And Elderly Patients with CLL
Case 3: Risk Assessment And Elderly Patients with CLL
Case 3: Intolerance to BTK Inhibitors in CLL
Case 3: Intolerance to BTK Inhibitors in CLL
Case 4: A Patient With Relapsed/Refractory CLL
Case 4: A Patient With Relapsed/Refractory CLL
Case 4: Resistance to Ibrutinib in CLL
Case 4: Resistance to Ibrutinib in CLL
Case 4: Treatment of Relapsed CLL
Case 4: Treatment of Relapsed CLL
Additional Insights: Treatment Regimens in CLL
Additional Insights: Treatment Regimens in CLL
Additional Insights: Management of Ibrutinib in CLL
Additional Insights: Management of Ibrutinib in CLL

Multiple Myeloma

Case 1: 51-Year-Old Man With Standard-Risk Myeloma
Case 1: 51-Year-Old Man With Standard-Risk Myeloma
Case 1: Triple or Quad Therapies for Standard-Risk Myeloma
Case 1: Triple or Quad Therapies for Standard-Risk Myeloma
Case 1: Choosing the Right Therapy for Standard-Risk Myeloma
Case 1: Choosing the Right Therapy for Standard-Risk Myeloma
Case 1: Treatment-Associated Toxicities in Myeloma
Case 1: Treatment-Associated Toxicities in Myeloma
Case 2: 64-Year-Old Woman With High-Risk Myeloma
Case 2: 64-Year-Old Woman With High-Risk Myeloma
Case 2: Determining Risk in Myeloma
Case 2: Determining Risk in Myeloma
Case 2: Overcoming High Risk in Myeloma
Case 2: Overcoming High Risk in Myeloma
Case 2: Use of Genomic Sequencing in Myeloma
Case 2: Use of Genomic Sequencing in Myeloma
Case 2: Supportive Care for Patients With Myeloma
Case 2: Supportive Care for Patients With Myeloma
Case 3: An Elderly Patient With Newly Diagnosed Myeloma
Case 3: An Elderly Patient With Newly Diagnosed Myeloma
Case 3: Geriatric Assessment in Myeloma
Case 3: Geriatric Assessment in Myeloma
Case 3: Treatment Considerations for Elderly Patients With Myeloma
Case 3: Treatment Considerations for Elderly Patients With Myeloma
Case 4: Relapsed-Refractory Myeloma
Case 4: Relapsed-Refractory Myeloma
Case 4: Treatment Considerations for High-Risk and Standard-Risk R/R Myeloma
Case 4: Treatment Considerations for High-Risk and Standard-Risk R/R Myeloma